An in-vitro study to evaluate the anti-bacterial activity of cantharis in various potencies against uropathogenic Escherichia coli

Sibin RA, Manikutty VS, Mugalyaa PR, Muthumari M, Nayana MR and Vidya V

DOI: https://doi.org/10.33545/26164485.2024.v8.i1e.1089

Abstract

Background: In the human intestine, Escherichia coli, also known as E. coli, is a prevalent bacterium. The specific strain of E. coli responsible for Urinary Tract Infections (UTIs) is referred to as Uropathogenic E. Coli (UPEC). Recent results from the Global Antimicrobial Surveillance System (GLASS) conducted by the WHO reveal a troubling prevalence of antibiotic resistance, with E. Coli standing out as the most frequently documented resistant bacteria. Cantharis is one of the most profoundly prescribed Homoeopathic medicines in case of UTIs in clinical practice. This study focuses on assessing the in vitro antibacterial action of the Homoeopathic medicine Cantharis against Uropathogenic E. coli.

Materials and Methods: The Homoeopathic Medicine Cantharis in Q, 30C, 200 C, and 1M was tested for antibacterial activity using the Kirby-Bauer Disk Diffusion test. The colonies of the uropathogenic strain of E. Coli were cultured in nutrient broth and inoculated on Muller-Hinton Agar plates. The discs impregnated with Homoeopathic medicine Cantharis in Q, 30C, 200 C, and 1M and Vehicle control (Ethanol 90%) were placed in MHA plates and left for 24 hours at 37 °C after which the zone of inhibition was measured.

Results: The zone of growth inhibition around Cantharis Q, 30C, 200 C, and 1M, and control was (1.6±0.1) c.m., (1.6±0.1) c.m., (0.6±0.1) c.m., and 0.6 c.m. respectively.

Conclusion: Cantharis Q and 30C exhibited the maximum Growth Inhibitory Zone against Escherichia coli compared to the control.

Keywords: Anti-bacterial, bacteriolytic, cantharis, Escherichia coli, homoeopathy

Introduction

A gram-negative, facultatively anaerobic bacterium that is frequently found in the colon is called Escherichia coli[1]. Though they are generally harmless, they can cause various health issues among which UTI is the commonest disease which is caused by the uropathogenic strains of E. Coli. Other diseases such as Gastroenteritis, Neonatal meningitis, and in rare cases, Septicaemia, Mastitis, Pneumonia etc are caused by different strains of E. Coli through the feco-oral route[2, 6]. A urinary tract infection (UTI) is characterized by the detection of a specific bacterial count in the urine, typically exceeding 105/ml. In clinical terms, UTIs are classified as either uncomplicated or complicated based on the existence of structural or neurological abnormalities within the urinary tract. Symptomatic UTIs are categorized by severity, including urosepsis syndrome, pyelonephritis (an upper UTI involving kidney infection) which occurs when the bacteria ascend to the kidneys through ureters from the biofilm in the urinary bladder, and cystitis (a lower UTI involving bladder infection) when the colonization of bacterium is limited to the bladder alone [3, 4]. Approximately 150 million individuals globally experience urinary tract infections (UTIs) annually, resulting in significant societal burdens. An estimated 40% of women encounter at least one UTI throughout their lives, and around 11% of women aged 18 and above suffer from a UTI episode each year [5].

Antibiotic resistance of E. Coli

After the invention of the antibiotic Penicillin by Alexander Fleming the infectious diseases were under control. However, due to the extensive use of antibiotics, the pathogenic microbes developed drug resistance against them [9].
The WHO has introduced a Global Priority Pathogens List (Global PPL) and the GLASS to prioritize research and development of new antibiotics. The global PPL categorizes antibiotic-resistant bacteria into three priority tiers (I, II, III): Critical, High and Medium. Enterobacteriaceae species, which includes Escherichia coli, are in Priority I (Critical). GLASS indicates widespread antibiotic resistance, with E. coli being the most commonly reported resistant bacteria. Across countries, the proportion of patients with bacteria resistant to commonly used antibiotics varies significantly, ranging from 8% to 65%. In a retrospective study conducted at a Mumbai tertiary healthcare hospital to assess current antibiotic sensitivity patterns in uropathogens causing UTIs, the data revealed an overall UTI prevalence of 33.54%, with 66.78% in females and 33.22% in males. Prevalence was higher in females, particularly those aged 31 to 45, and in males above 45. Escherichia coli (53.77%) and Klebsiella pneumoniae (27.40%) were the main isolates. Effective antibiotics included meropenem, gentamicin, nitrofurantoin, and cotrimoxazole, while resistance was higher in fluoroquinolones, amoxicillin, and third-generation cephalosporins. The findings highlight the evolving drug resistance landscape, emphasizing the necessity for regular surveillance to update physicians for more precise empirical UTI treatment strategies.

**Homoeopathy for UTI**

Homoeopathy is the second most commonly used complementary medicine across the world. The Homoeopathic Medicine Cantharis vesicatoria is widely used in the treatment of UTI although many other remedies have been used. In a Randomized Double-Blind Placebo Controlled Trial of Cantharis Vesicaria in Urinary Tract Infection, 30 patients in the treatment group received Cantharis vesicaria, while those in the placebo group were administered a placebo mother tincture for 6 months. The findings revealed a significant outcome for Cantharis vesicaria, with a p-value of 0.05. Consequently, Cantharis vesicaria may be regarded as a viable supplement for treating urinary tract infections. Another case study highlights the successful use of Cantharis 30CH, in Acute Urinary Tract Infection (UTI) in a 4-month-old infant. The parents, hesitant about antibiotics, opted for homoeopathic treatment for their infant. The Homoeopathic medicine Cantharis, dissolved in breast milk, was administered thrice daily and produced noticeable improvement within three days and complete resolution of symptoms in six days. The results suggest that a well-chosen Homoeopathic simillimum, in the right potency and dosage, can effectively address *E. Coli* infections even in infants.

**Indications of Cantharis for Urinary complaints**


**Materials and Methods**

The antibacterial efficacy of the sample was assessed using the disk diffusion method on the Muller Hinton agar (MHA) medium. A variety of non-fastidious organisms can be grown in Muller-Hinton agar, which is a non-selective and non-differential media. A mixture of 3.8 gm of Muller Hinton agar was dissolved in 100ml of distilled water, supplemented with 1gm of agar, and subjected to sterilization. Subsequently, the sterilized medium was poured into sterile petri plates and allowed to solidify for one hour. After solidification, sterile swabs moistened in *E. Coli* bacterial suspension were used to spread the inoculates on the solid MHA plates. Plain discs were impregnated with varying potencies (30C, 200C, 1M) and the mother tincture of Cantharis, along with the vehicle control (ethanol 90%). These prepared discs were then placed on MHA plates and incubated for 24 hours at 37°C. The extent of microbial growth inhibition was determined by measuring the diameter of the zone of inhibition surrounding the discs. The zone of inhibition around the wells was measured to screen the antibacterial activity of *E. Coli*.

**Results**

The zone of growth inhibition around Cantharis Q, 30C, 200C, 1M, and control was (1.6±0.1) c.m., (1.6±0.1) c.m., (0.8±0.1) c.m., (0.6±0.1) c.m. and 0.6 c.m. respectively.

**Table 1: Antibacterial activity of Homoeopathic medicine Cantharis against E. Coli**

<table>
<thead>
<tr>
<th>Homoeopathic medicine</th>
<th>Zone of Inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Set I</td>
</tr>
<tr>
<td>Cantharis Q</td>
<td>1.7 cm</td>
</tr>
<tr>
<td>Cantharis 30 CH</td>
<td>1.7 cm</td>
</tr>
<tr>
<td>Cantharis 200 CH</td>
<td>0.8 cm</td>
</tr>
<tr>
<td>Cantharis 1M</td>
<td>0.6 cm</td>
</tr>
<tr>
<td>Control (Ethanol)</td>
<td>0.6 cm</td>
</tr>
</tbody>
</table>

**Discussion**

The objective of this study was to assess the *in vitro* antibacterial effectiveness of Homoeopathic Medicine Cantharis in Mother tincture (Q) and various liquid potencies (30 C, 200 C, and 1M) against uropathogenic *E. Coli* strain. The experimental results revealed that Homoeopathic medicine exhibited a more significant reduction in the growth of the bacteria in Q, and 30CH compared to the Vehicle control (90% ethanol). Despite the well-known antibiotic properties of alcohol with strengths ranging from 60% to 90% v/v, the observed antibacterial activity of Homoeopathic medicine surpassed that of the ethanol control. This supports the notion that the observed zone of inhibition of *E. Coli* bacteria by Homoeopathic medicine was not attributed to ethanol; rather, some
dynamic pharmacological actions were responsible. In a study conducted using a cystitis-induced mice model to investigate the efficacy of the Homoeopathic medicine Cantharis against UPEC. In this study, Cantharis 6cH or a placebo was administered through drinking water (1:100) for 24 hours post-infection in 24 adult susceptible female BALB/c mice. The results indicated that Cantharis 6 CH induced specific local immune modulation, altering the balance of inflammatory cells and cytokines in the bladder and pelvis mucosa [10].

Conclusion
The results of this in vitro antibacterial study indicate that Homoeopathic medicine Cantharis Q and 30 CH exhibits a distinct growth inhibitory effect on uropathogenic E. Coli while Cantharis 200 CH showed minimal growth inhibitory effect. This supports the application of Homoeopathic Medicine Cantharis for treating Urinary Tract Infections, given its ability to inhibit the growth of the bacteria.

Conflict of Interest
Not available

Financial Support
Not available

References

How to Cite This Article

Creative Commons (CC) License
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.